News
Objectives To investigate baricitinib (LY3009104, formerly INCB028050), a novel, oral inhibitor of JAK1/JAK2 in patients with moderate to severe rheumatoid arthritis (RA) despite treatment with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback